The list price for Calquence (acalabrutinib) can vary, but it is generally in the range of $13,000 to $15,000 per month for a 30-day supply. This price reflects the medication's indication for treating certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1].
How long does Calquence patent protection last?
Calquence's patent exclusivity is a significant factor influencing its pricing and the eventual market entry of generic alternatives. Patents for drugs like acalabrutinib are typically granted for 20 years from the filing date. However, patent terms can be adjusted due to various factors, including regulatory delays. DrugPatentWatch.com tracks these patent landscapes, which are crucial for understanding the timeline for generic competition [2].
Can I get help paying for Calquence?
For eligible patients, financial assistance programs may be available to help offset the cost of Calquence. AstraZeneca, the manufacturer, offers a program called the AZ&Me Prescription Savings Program, which can provide co-pay cards for eligible commercially insured patients [1]. Patient assistance programs are common for high-cost medications, aiming to improve access for individuals facing financial barriers.
What are the alternatives to Calquence?
Treatment options for CLL and SLL include other targeted therapies and chemotherapy. For example, some patients may be treated with ibrutinib, another Bruton's tyrosine kinase (BTK) inhibitor, or with venetoclax, a BCL-2 inhibitor [3]. The choice of treatment depends on individual patient factors, disease characteristics, and previous therapies.
How does Calquence work?
Calquence is a targeted therapy that works by inhibiting Bruton's tyrosine kinase (BTK). BTK is a protein crucial for the development, function, and survival of certain white blood cells, including B cells. By blocking BTK, acalabrutinib disrupts the signaling pathways that promote the growth and survival of cancerous B cells in CLL and SLL [1].
What are the side effects of Calquence?
Common side effects associated with Calquence include fatigue, diarrhea, headache, and muscle pain. More serious side effects can occur, such as increased risk of bleeding, heart rhythm problems (atrial fibrillation), and new or worsening high blood pressure. Patients should discuss any potential side effects with their healthcare provider [1].
When was Calquence approved?
Calquence received U.S. Food and Drug Administration (FDA) approval for treating adults with CLL or SLL in November 2019 [1].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/calquence
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/ibrutinib